search
Back to results

Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap

Primary Purpose

Myopia

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
FS200 Femtosecond Laser
Sponsored by
Durrie Vision
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia focused on measuring Lasik, Myopia, Femtosecond Laser

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA

The following are requirements for a potential study patient's inclusion into the study:

  • Male or female in good general health, 18 years of age or older at the time of the pre-operative examination
  • Patient must be able to read, comprehend and willing to give HIPPA and informed consent
  • Patient is planning to undergo a bilateral LASIK procedure
  • Both eyes must have a manifest refractive error from -1.00 to -7.00D spherical equivalent with less than or equal to 3.00 D of refractive astigmatism as expressed in spectacle minus cylinder form
  • Both eyes must have a BSCVA of 20/25 or better
  • Both eyes must demonstrate refractive stability confirmed by clinical records or previous glasses. Refractive stability shall be documented by a change of less than or equal to 0.50 diopter per year (sphere and cylinder) or as documented by clinical judgment by the investigator.

EXCLUSION CRITERIA

The following are exclusion criteria for study patients in this study:

  • A patient with evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye
  • A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye during the study period with the exception of ocular drops and/or medications provided by the investigator
  • A patient having any surgical procedure within a week preceding the scheduled LASIK surgery
  • A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom therapy for a systemic disease is not yet stabilized )
  • A patient with a history of prior intraocular or corneal surgery (including cataract extraction), clinically significant ophthalmic disease or abnormality (including, but not limited to, uncontrolled clinically significant blepharitis, clinically significant recurrent corneal erosion, clinically significant dry eye syndrome, clinically significant lens opacity, evidence of clinically significant trauma (including scarring inside the visual axis), or evidence of glaucoma or propensity for narrow angle glaucoma in either eye
  • A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results
  • A patient with a history of any of the following medical conditions, or any other condition that could affect wound healing: uncontrolled diabetes, collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
  • A female patient who is pregnant, nursing, planning a pregnancy during the study, or thinks she may be pregnant at the start of the study
  • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational device research study.

Sites / Locations

  • Durrie Vision

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

FS200 Femtosecond Laser

Arm Description

The LASIK flap will be created using the FS200 Femtosecond Laser

Outcomes

Primary Outcome Measures

Flap Thickness
The flap thickness will be measured one week postoperative using the Visante OCT and the Optivue OCT devices

Secondary Outcome Measures

Change in Uncorrected Visual Acuity at 1 Day, 1 Week, and 1 Month Postoperatively
Change in Uncorrected visual acuity will be measured at 1 Day, 1 week, and 1 month postoperatively

Full Information

First Posted
September 21, 2012
Last Updated
January 24, 2013
Sponsor
Durrie Vision
Collaborators
Alcon Research
search

1. Study Identification

Unique Protocol Identification Number
NCT01693939
Brief Title
Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
Official Title
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Durrie Vision
Collaborators
Alcon Research

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to document the programmed flap thickness to achieved flap thickness using the FS200 femtosecond laser in performing LASIK procedure. The FS200 Femtosecond laser is a precision surgical device that is used to create a flap in a FDA approved LASIK procedure.
Detailed Description
The objective of this study is to evaluate the thickness of the corneal flap created with the FS 200 Femtosecond laser flap during the LASIK procedure using the Visante and OptiVue OCT ultrasound devices.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia
Keywords
Lasik, Myopia, Femtosecond Laser

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FS200 Femtosecond Laser
Arm Type
Other
Arm Description
The LASIK flap will be created using the FS200 Femtosecond Laser
Intervention Type
Device
Intervention Name(s)
FS200 Femtosecond Laser
Primary Outcome Measure Information:
Title
Flap Thickness
Description
The flap thickness will be measured one week postoperative using the Visante OCT and the Optivue OCT devices
Time Frame
1 Week Postoperative visit
Secondary Outcome Measure Information:
Title
Change in Uncorrected Visual Acuity at 1 Day, 1 Week, and 1 Month Postoperatively
Description
Change in Uncorrected visual acuity will be measured at 1 Day, 1 week, and 1 month postoperatively
Time Frame
Postoperatively 1 month
Other Pre-specified Outcome Measures:
Title
Postoperative Satisfaction Survey over Time
Description
Subject questionnaire will be administered to evaluate overall patient satisfaction postoperatively
Time Frame
Postoperatively Day 1, Week 1, Month 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA The following are requirements for a potential study patient's inclusion into the study: Male or female in good general health, 18 years of age or older at the time of the pre-operative examination Patient must be able to read, comprehend and willing to give HIPPA and informed consent Patient is planning to undergo a bilateral LASIK procedure Both eyes must have a manifest refractive error from -1.00 to -7.00D spherical equivalent with less than or equal to 3.00 D of refractive astigmatism as expressed in spectacle minus cylinder form Both eyes must have a BSCVA of 20/25 or better Both eyes must demonstrate refractive stability confirmed by clinical records or previous glasses. Refractive stability shall be documented by a change of less than or equal to 0.50 diopter per year (sphere and cylinder) or as documented by clinical judgment by the investigator. EXCLUSION CRITERIA The following are exclusion criteria for study patients in this study: A patient with evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye during the study period with the exception of ocular drops and/or medications provided by the investigator A patient having any surgical procedure within a week preceding the scheduled LASIK surgery A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom therapy for a systemic disease is not yet stabilized ) A patient with a history of prior intraocular or corneal surgery (including cataract extraction), clinically significant ophthalmic disease or abnormality (including, but not limited to, uncontrolled clinically significant blepharitis, clinically significant recurrent corneal erosion, clinically significant dry eye syndrome, clinically significant lens opacity, evidence of clinically significant trauma (including scarring inside the visual axis), or evidence of glaucoma or propensity for narrow angle glaucoma in either eye A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results A patient with a history of any of the following medical conditions, or any other condition that could affect wound healing: uncontrolled diabetes, collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis A female patient who is pregnant, nursing, planning a pregnancy during the study, or thinks she may be pregnant at the start of the study Current participation or participation within 30 days prior to the start of this study in a drug or other investigational device research study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel S. Durrie, MD
Organizational Affiliation
Durrie Vision
Official's Role
Principal Investigator
Facility Information:
Facility Name
Durrie Vision
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66211
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap

We'll reach out to this number within 24 hrs